FGFR4 (V550L)
Sign in to save this workspaceFGFR4 · Variant type: point · HGVS: p.V550L
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Brigatinib | 92.7% | 7.3% | 82.96 |
| 2 | Futibatinib | 90.3% | 9.7% | 98.48 |
| 3 | Ceritinib | 68.5% | 31.5% | 95.44 |
| 4 | Erdafitinib | 58.6% | 41.4% | 95.71 |
| 5 | Pralsetinib | 54.2% | 45.8% | 93.43 |
| 6 | Selpercatinib | 42.3% | 57.7% | 96.72 |
| 7 | Defactinib | 37.4% | 62.6% | 92.68 |
| 8 | Upadacitinib | 32.8% | 67.2% | 97.98 |
| 9 | Alectinib | 30.4% | 69.6% | 95.49 |
| 10 | Fedratinib | 29.9% | 70.1% | 96.21 |
| 11 | Pemigatinib | 28.1% | 71.9% | 98.23 |
| 12 | Alpelisib | 26.2% | 73.8% | 97.22 |
| 13 | Sunitinib | 25.9% | 74.1% | 91.73 |
| 14 | Repotrectinib | 20.7% | 79.3% | 84.21 |
| 15 | Ponatinib | 19.6% | 80.4% | 78.23 |
| 16 | Pacritinib | 18.8% | 81.2% | 88.64 |
| 17 | Entrectinib | 18.4% | 81.6% | 93.69 |
| 18 | Neratinib | 12.2% | 87.8% | 93.18 |
| 19 | Infigratinib | 10.1% | 89.9% | 98.24 |
| 20 | Pirtobrutinib | 8.2% | 91.8% | 99.49 |
| 21 | Trametinib | 8.1% | 91.9% | 99.50 |
| 22 | Tenalisib | 7.8% | 92.2% | 97.98 |
| 23 | Nintedanib | 7.4% | 92.6% | 90.23 |
| 24 | Apatinib | 7.1% | 92.9% | 97.73 |
| 25 | Gilteritinib | 6.9% | 93.1% | 88.97 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Brigatinib | 92.7% | 73.3% | +19.4% |
| Futibatinib | 90.3% | 97.9% | -7.7% |
| Ceritinib | 68.5% | 48.2% | +20.3% |
| Erdafitinib | 58.6% | 98.0% | -39.5% |
| Pralsetinib | 54.2% | 64.6% | -10.4% |
| Selpercatinib | 42.3% | 49.1% | -6.9% |
| Defactinib | 37.4% | — | — |
| Upadacitinib | 32.8% | — | — |
| Alectinib | 30.4% | 36.3% | -5.9% |
| Fedratinib | 29.9% | — | — |
| Pemigatinib | 28.1% | 93.9% | -65.8% |
| Alpelisib | 26.2% | 96.8% | -70.6% |
| Sunitinib | 25.9% | — | — |
| Repotrectinib | 20.7% | — | — |
| Ponatinib | 19.6% | 96.7% | -77.1% |
| Pacritinib | 18.8% | — | — |
| Entrectinib | 18.4% | — | — |
| Neratinib | 12.2% | — | — |
| Infigratinib | 10.1% | 94.7% | -84.7% |
| Pirtobrutinib | 8.2% | — | — |
| Trametinib | 8.1% | — | — |
| Tenalisib | 7.8% | 83.9% | -76.1% |
| Nintedanib | 7.4% | 33.7% | -26.4% |
| Apatinib | 7.1% | — | — |
| Gilteritinib | 6.9% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| rhabdomyosarcoma_soft_tissue | Soft Tissue | ref |
| carcinoma_breast | Breast | ref |
| malignant_fibrous_histiocytoma-pleomorphic_sarcoma_soft_tissue | Soft Tissue | ref |
| carcinoma_endometrium | Uterus | ref |
| UCEC-US | Uterus | ref |
| UCEC | Uterus | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.9ms